Spero Therapeutics, Inc.
SPRO evidence brief
What we can confirm
- BioSniper Score:
- 7.1 / 10
- Market Cap:
- $65.8M
- Lead Asset:
- spr206 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for SPRO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SPRO
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on rare diseases and high-unmet-need conditions, with an approved oral antibiotic (Utebzi) and a newly in-licensed immunology asset (SP001).
Key risk: No product revenue
BioSniper Score
Based on 4 of 6 signals
Market Cap
$65.8M
Cash Runway
—
Lead Asset
spr206 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for Spero Therapeutics, Inc..
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on rare diseases and high-unmet-need conditions, with an approved oral antibiotic (Utebzi) and a newly in-licensed immunology asset (SP001).
- FDA approved Utebzi™ (tebipenem pivoxil), the first oral carbapenem antibiotic for complicated urinary tract infections in adults [news · 2026-08-12].
- Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready anti-CD40L antibody for immune-mediated diseases [news · 2026-08-12].
- Closed $105 million non-recourse, non-dilutive financing backed by future Utebzi milestones and royalties [news · 2026-08-12].
- Cash and cash equivalents of $50.8 million as of June 30, 2026 [sec_mda · as of 2026-08-12].
- Accumulated deficit of $467.8 million as of June 30, 2026 [sec_mda · as of 2026-08-12].
What works
- FDA approval of Utebzi provides a revenue-generating product and validates the company's core antibiotic platform [news · 2026-08-12].
- The $105 million non-dilutive financing extends cash runway into 2029 without diluting equity [news · 2026-08-13].
- In-licensing of SP001 adds a Phase 2-ready asset targeting a rare disease (IgG4-RD) with potential for multiple indications [sec_mda · as of 2026-08-12].
What to weigh
- Spero has no product revenue and reported net income of -$9.6M for the period ending June 30, 2026 [latest reported financials].
- Accumulated deficit of $467.8 million as of June 30, 2026 reflects sustained operating losses [sec_mda · as of 2026-08-12].
- Future profitability depends heavily on successful development of SP001 and GSK's commercialization of Utebzi, both of which are uncertain [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
FDA approval of Utebzi
“U.S. Food and Drug Administration approved Utebzi™ (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis”
News · August 12, 2026
SP001 in-license agreement
“Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases”
News · August 12, 2026
Cash and cash equivalents as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $467.8 million, and cash and cash equivalents of $50.8 million.”
SEC MD&A · August 12, 2026
Non-dilutive financing
“Closed $105 million non-recourse, non-dilutive financing backed by a portion of future Utebzi milestones and royalties, extending cash runw”
News · August 12, 2026
Risks & what to watch (3)›
Key risks
- No product revenue — Company reported $0.0M total revenue as of 2026-06-30 [latest reported financials].
- Dependence on GSK — Profitability relies on GSK's commercialization of Utebzi and successful development of SP001 [sec_mda · as of 2026-08-12].
- Accumulated deficit — Accumulated deficit of $467.8M as of 2026-06-30 indicates sustained cash burn [sec_mda · as of 2026-08-12].
What to watch
- GSK's commercial launch and sales trajectory of Utebzi following FDA approval [news · 2026-08-12].
- Initiation of Phase 2 trial for SP001 in IgG4-RD planned for Q2 2027 [news · 2026-07-14].
- Innovent's Phase 2 trial for SP001 in Sjögren's disease in China by early 2027 [news · 2026-07-14].
- Cash runway extension into 2029 and any further financing or partnership developments [news · 2026-08-13].
Sources: News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Spero Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Spero Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.19 · 0% dilution
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
50
Total value held
$48.6M
| Holder | Shares | Value |
|---|---|---|
| gsk plc | 9,190,606 | $21.5M |
| pfizer inc | 2,362,348 | $5.5M |
| vanguard capital management llc | 1,799,880 | $4.2M |
| renaissance technologies llc | 1,189,235 | $2.8M |
| alphabet inc. | 889,979 | $2.1M |
| two sigma investments, lp | 885,631 | $2.1M |
| anson funds management lp | 843,912 | $2.0M |
| geode capital management, llc | 519,922 | $1.2M |
| blackrock, inc. | 433,202 | $1.0M |
| citadel advisors llc | 376,458 | $881K |
Showing top 10 of 50 institutional holders of Spero Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 1.3%
- Days to cover
- 1.9
- Shares short
- 605,311
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SPRO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Spero Therapeutics, Inc.?
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on rare diseases and high-unmet-need conditions, with an approved oral antibiotic (Utebzi) and a newly in-licensed immunology asset (SP001).
What is Spero Therapeutics, Inc.'s lead drug candidate?
Spero Therapeutics, Inc.'s most advanced tracked candidate is spr206 (Phase 2) for MDR Gram-negative bacterial infections.
Who is the CEO of Spero Therapeutics, Inc.?
Ms. Esther P. Rajavelu is the chief executive officer of Spero Therapeutics, Inc. (SPRO).
Where is Spero Therapeutics, Inc. headquartered?
Spero Therapeutics, Inc. (SPRO) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Spero Therapeutics, Inc. focus on?
Spero Therapeutics, Inc. develops therapies across Oncology, Infectious Disease, Metabolic, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.